Sanofi, Re­gen­eron build their case for yet an­oth­er ap­proval for im­munol­o­gy star Dupix­ent

Over the week­end Sanofi and Re­gen­eron post­ed an­oth­er up­beat round of da­ta from their Phase III pro­gram for the pow­er­house Dupix­ent — this time in eosinophilic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER